Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyond

Paul Horn; Philip N. Newsome

doi:10.1111/apt.15509

Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyond

Immunology and Immunotherapy

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	199-200
Number of pages	2
Journal	Alimentary Pharmacology & Therapeutics
Volume	51
Issue number	1
DOIs	https://doi.org/10.1111/apt.15509
Publication status	Published - 18 Dec 2019

Bibliographical note

Funding Information:
Declaration of personal interests : Dr Newsome reports consultancy/speaker fees on behalf of the University of Birmingham from Boehringer Ingelheim, Dignity Sciences, Gilead, Intercept, Johnson & Johnson, Novo Nordisk, Pfizer, Poxel Pharmaceuticals and Shire. His institution receives grant funding from Pharmaxis, Boehringer Ingelheim and Novo Nordisk. Dr Horn reports scientific collaboration with Novo Nordisk, Geratherm respiratory GmbH and UST Umweltsensortechnik and funding from Novo Nordisk.

Funding Information:
The authors' research is funded and supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the NHS.

ASJC Scopus subject areas

Hepatology
Gastroenterology
Pharmacology (medical)

Access to Document

10.1111/apt.15509

Cite this

@article{48bebaefb95246aab6b373e77e456d9a,

title = "Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyond",

author = "Paul Horn and Newsome, {Philip N.}",

note = "Funding Information: Declaration of personal interests : Dr Newsome reports consultancy/speaker fees on behalf of the University of Birmingham from Boehringer Ingelheim, Dignity Sciences, Gilead, Intercept, Johnson & Johnson, Novo Nordisk, Pfizer, Poxel Pharmaceuticals and Shire. His institution receives grant funding from Pharmaxis, Boehringer Ingelheim and Novo Nordisk. Dr Horn reports scientific collaboration with Novo Nordisk, Geratherm respiratory GmbH and UST Umweltsensortechnik and funding from Novo Nordisk. Funding Information: The authors' research is funded and supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the NHS.",

year = "2019",

month = dec,

day = "18",

doi = "10.1111/apt.15509",

language = "English",

volume = "51",

pages = "199--200",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Commentary: advances in the pharmacotherapy of NASH-anti-diabetic drugs and beyond

AU - Horn, Paul

AU - Newsome, Philip N.

N1 - Funding Information: Declaration of personal interests : Dr Newsome reports consultancy/speaker fees on behalf of the University of Birmingham from Boehringer Ingelheim, Dignity Sciences, Gilead, Intercept, Johnson & Johnson, Novo Nordisk, Pfizer, Poxel Pharmaceuticals and Shire. His institution receives grant funding from Pharmaxis, Boehringer Ingelheim and Novo Nordisk. Dr Horn reports scientific collaboration with Novo Nordisk, Geratherm respiratory GmbH and UST Umweltsensortechnik and funding from Novo Nordisk. Funding Information: The authors' research is funded and supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care or the NHS.

PY - 2019/12/18

Y1 - 2019/12/18

UR - https://doi.org/10.1111/apt.15509

U2 - 10.1111/apt.15509

DO - 10.1111/apt.15509

M3 - Comment/debate

SN - 0269-2813

VL - 51

SP - 199

EP - 200

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

IS - 1

ER -